Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the composition of its board of directors and their respective roles within the company. This announcement highlights the company’s commitment to strong governance and strategic leadership, which could positively influence its market position and stakeholder confidence.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on the development and commercialization of biopharmaceutical products, with a market focus on innovative therapies.
Average Trading Volume: 906,033
Technical Sentiment Signal: Buy
Current Market Cap: HK$79.89B
See more data about 6990 stock on TipRanks’ Stock Analysis page.